Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Capital Goods
Near term
6-12 MONTHS
We expect a gradual recovery of organic growth through 2027. Bergman & Beving (B&B) has cut costs and reduced the number of unprofitable products. Once volumes return, we expect margins to expand at an even faster rate.
Long term
6+ YEARS
We expect B&B to continue making acquisitions and expand margins in the years to come. It had set a target to reach EBIT of at least SEK500m, with an EBIT margin above 10%, no later than 2025/26. It was not able to meet this because of the divestment of Skydda, but we believe it can get there in the next few years, at which time new targets are likely to be set. The timing depends on the pace of M&A – the company aims for acquisitions to support earnings by adding EBIT of SEK50m–80m per year. It also aims to reach a profitability target of P/WC (profit over working capital) of 45% no later than 2026/27.
The business cycle.
Deterioration in the M&A market.
That future acquisitions fall shy of expectations.
Increased competition for M&A targets.
Price
Fair range high value
Fair range low value
The lower end of our multiples range is based on a three-year sales CAGR of 2% and EBITA CAGR of 7%, while the higher end is based on a three-year sales CAGR of 4% and EBITA CAGR of 12%. In our M&A analysis, we assume a 10% sales CAGR and 12% EBITA CAGR for 2025/26–2036/37 at the low end; the upper end assumes a 13% sales CAGR and 15% EBITA CAGR.
Our fair value range is based on two scenarios applied to multiples-based valuations as well as M&A analysis. We use a P/E of 33x and an EV/EBITA of 20x on our 2027/28 estimates and discount the values back to today. These multiples are below the mature compounders (Addtech, Lagercrantz, Indutrade and Lifco. Bergman & Beving has the same background as the mature compounders, but also a more limited history in its current form. In our M&A scenario analysis, we add acquisitions to sales and earnings. This is relevant as acquisitions are the main sales and earnings driver.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB